Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...7891011121314151617...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Retrospective data, Journal, HEOR, Metastases:  Comparative Effectiveness of Cetuximab Versus Panitumumab in Patients With Metastatic Colorectal Cancer: A Nationwide Database Study. (Pubmed Central) -  Nov 4, 2023   
    Though panitumumab- and cetuximab-based therapies showed no differences, several factors, such as age over 70 years old, tumor stage 4B and 4C, undifferentiated carcinoma, mucinous carcinoma, right-sided tumor, number of positive lymph nodes, obstruction, and primary tumor resection increased the mortality risk of patients. This study underscores the importance of metastasectomy in current treatment guidelines and future clinical trials.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, temuterkib (LY3214996) / Eli Lilly, Verzenio (abemaciclib) / Eli Lilly
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) -  Oct 31, 2023   
    P1b/2,  N=46, Active, not recruiting, 
    Combination treatment with afatinib and cetuximab demonstrated antitumor activity with a DCR of 54% at 18 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zokinvy (lonafarnib) / Eiger
    PK/PD data, Preclinical, Journal:  A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro. (Pubmed Central) -  Oct 30, 2023   
    An overall synergistic relationship (interaction index?=?1.03E-8) was detected in the in vitro experiment. In the in vivo model, the overall interaction index was 70,139.45 implying an antagonistic interaction between the cisplatin and the cetuximab signals.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  CIFRA: Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (clinicaltrials.gov) -  Oct 30, 2023   
    P2,  N=34, Recruiting, 
    Furthermore, the results were similar for patients who were previously treated with triplet regimen. Trial completion date: Mar 2023 --> Jan 2024 | Trial primary completion date: Mar 2022 --> Jan 2024
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cathepsin L-mediated EGFR cleavage affects intracellular signalling pathways in cancer. (Pubmed Central) -  Oct 27, 2023   
    Furthermore, we determined the effect of truncated EGFR protein expression on HeLa cell viability and response to the EGFR inhibitors, tyrosine kinase inhibitor (TKI) erlotinib and monoclonal antibody (mAb) cetuximab. Our data reveal the nuclear localization and phosphorylation of EGFR and signal trancducer and activator of transcription 3 (STAT3) in cells that express the truncated EGFR protein and suggest that these phenomena cause resistance to EGFR inhibitors.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Fluorine-18 and Radiometal Labeling of Biomolecules via Disulfide Rebridging. (Pubmed Central) -  Oct 26, 2023   
    We next extended our strategy to the radiolabeling of cetuximab, a monoclonal antibody, with various radiometals commonly used in PET imaging (zirconium-89, copper-64) by developing various rebridging molecules bearing the appropriate chelators. The stabilities of the radiolabeled antibody conjugates were assessed in biological conditions.
  • ||||||||||  monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
    Trial completion date, IO biomarker, Metastases:  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) -  Oct 24, 2023   
    P1/2,  N=383, Active, not recruiting, 
    The stabilities of the radiolabeled antibody conjugates were assessed in biological conditions. Trial completion date: Jun 2023 --> Sep 2024
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment change, Trial withdrawal, Tumor cell:  Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC (clinicaltrials.gov) -  Oct 19, 2023   
    P2,  N=0, Withdrawn, 
    Notably both right-sided and left-sided CMS2 tumors had excellent response, suggesting that anti-EGFR therapy be included as a treatment option for right-sided CMS2 tumors. N=40 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Anniko (penpulimab) / Akesobio, Sino Biopharm, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN (clinicaltrials.gov) -  Oct 18, 2023   
    P2,  N=48, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jan 2024 --> Dec 2024
  • ||||||||||  CIML NK - Dana / Farber Cancer Institute
    Trial primary completion date, Combination therapy, Metastases, Immune cell:  CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) -  Oct 17, 2023   
    P1,  N=25, Recruiting, 
    Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jan 2024 --> Dec 2024 Trial primary completion date: Sep 2023 --> Jan 2024
  • ||||||||||  Real-world analysis of biomarker testing and actionability in metastatic colorectal cancer (mCRC) in the United States (US). (3rd Floor, Back Bay Hall; Poster Bd #: B22) -  Oct 13, 2023 - Abstract #ASCOQC2023ASCO_QC_384;    
    Current real-world biomarker testing rates reflect increased adoption of clinical guideline recommendations, leading to improved treatment actionability as shown by sustained administration of targeted therapies (BRAF), increased administration of immunotherapy (MSI-H), and less frequent use of potentially inappropriate treatments (RAS). Further improvements in testing and receipt of appropriate therapies may lead to better patient outcomes.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Molecular docking analysis of cetuximab with NOTCH signalling pathway targets for oral cancer. (Pubmed Central) -  Oct 12, 2023   
    Therefore, it is of interest to document the molecular docking analysis of cetuximab with the NOTCH signaling targets such as NOTCH1, NICD, and HES1. These results suggest that targeting the NOTCH signaling with cetuximab might leads to the better outcome for suppression of invasion and metastasis in oral carcinoma.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    P2 data, Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker:  SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. (Pubmed Central) -  Oct 10, 2023   
    Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_910;    
    Conclusions Acquired resistance to cetuximab was found to correlate with radiation-resistance but not erlotinib-resistance. Since cetuximab is an anti-EGFr monoclonal antibody and erlotinib is an anti-EGFr tyrosine kinase inhibitor, further studies are underway to investigate the role of downstream signaling events that may contribute to our understanding for the lack of cross-resistance between cetuximab and erlotinib.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_905;    
    In western countries where HPV+ OPC prevalence is high, induction TPF response rate in locally advanced HNSCC is around 70%; Erbitux and TP (Argiris in JCO2008) response rate is 86%...In our previous study from unresectable stage IVA & IVB betal-nuts related HNSCC patients in ASCO2023, flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion) with Biotherapy(EGFR or VEGFR-targeting)or Bio-immunotherapy had encouraging induction response with favorable toxicity to conversion surgery or definite CCRT...Aggressive induction therapy followed by mini-invasive surgery and then adjuvant CCRT with maintenance UFUR might be administered in selected patients with high induction response. Encouraging outcomes have been shown by sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_694;    
    The 1L regimen consists of Cet plus mFOLFOX6 or FOLFIRI, based on pts selection, followed by maintenance therapy with Cetuximab with or without chemotherapy (cohort A) or chemotherapy alone (cohort B)...The Cox proportional hazards model, after adjusting for age, sex, primary tumor location, metastatic site, and whether the primary tumor and metastases were resected or not, showed that compared with cohort B, cohort A was associated with a statistically significant longer OS (HR 0.43, 95% CI 0.25-0.73) and a longer PFS, although the difference was not statistically significant (HR 0.70, 95% CI 0.44-1.12). Conclusions Maintenance therapy with Cet can significantly improve OS in pts with LS RAS/BRAF wt mCRC and lead to a clinically meaningful improvement in PFS, although the statistical difference was not reached.
  • ||||||||||  PF-07799933 / Pfizer
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov) -  Oct 5, 2023   
    P1,  N=174, Recruiting, 
    Based on these values and the assumptions that encorafenib and its metabolites are stable in feces, the fraction of oral absorption was estimated to be at least ~86%. Trial completion date: Jan 2028 --> Apr 2027 | Trial primary completion date: Jul 2026 --> Oct 2025
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer (clinicaltrials.gov) -  Oct 4, 2023   
    P2,  N=50, Recruiting, 
    Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Sep 2022 --> Sep 2025
  • ||||||||||  MRTX1133 / Mirati, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS Inhibitor, in Colorectal Cancer Treatment. (Pubmed Central) -  Oct 3, 2023   
    The combination of MRTX1133 and cetuximab serves as a potential and promising therapeutic approach for colorectal cancer with KRAS mutation. KRAS is a frequent genetic mutation not only in colorectal cancer, but also in pancreatic and lung cancer, and the results of this study open new avenues for potential treatment of many cancer patients.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Reimbursement, US reimbursement, Journal, HEOR, Medicare, Real-world evidence, Real-world, Metastases:  Real-World Treatment Patterns of Older Adults with Locally Advanced SCCHN Using SEER-Medicare. (Pubmed Central) -  Oct 3, 2023   
    The standard of care for LA SCCHN is definitive therapy (DT), a combination of surgery and or radiation therapy (RT), with or without platinum-based chemotherapy/cetuximab (chemo), that has been shown to optimize long term disease control...Availability of IO was low due to approvals after 2017. These findings suggest a need for novel therapies that can improve outcomes in LA SCCHN.